See today's BioWorld Asia
To read the full story, subscribe or sign in.

Eucure out-licenses anti-OX40 MAb to Syncromune for intratumoral immunotherapy

Oct. 25, 2022
By Doris Yu
Biocytogen Pharmaceuticals Co. Ltd. subsidiary Eucure Biopharma Co. Ltd. has formed a partnership with Syncromune Inc. to combine Eucure’s YH-002 and two other active ingredients with Syncromune’s Syncrovax platform technology.
BioWorld Asia Deals and M&A Cancer China